S. Korean anti-cancer biosimilar Truxima wins approval in Australia

Lim Chang-won Reporter Posted : 2018-04-20 14:02 Updated : 2018-04-20 14:02
글씨작게 글씨크게

[Courtesy of Celltrion]


SEOUL -- Truxima, an anti-cancer biosimilar produced by South Korea's Celltrion, has been approved by Australian authorities. Celltrion said Friday it would pick up a local partner for the sale of Truxima.

Truxima, a biosimilar of Rituximab, or Rituxan, used to treat patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis, is also popular in Europe.

With approval from Australia's Therapeutic Goods Administration, Celltrion has sold Remsima, a copy of Janssen Biotech's Remicade treating rheumatoid arthritis and Crohn's disease. Celltrion has disclosed a plan to build a third plant overseas in an Asian country this year.